Investigating coping and stigma in people living with HIV through narrative medicine in the Italian multicentre non-interventional study DIAMANTE
- PMID: 37848464
- PMCID: PMC10582167
- DOI: 10.1038/s41598-023-44768-2
Investigating coping and stigma in people living with HIV through narrative medicine in the Italian multicentre non-interventional study DIAMANTE
Abstract
Antiretroviral therapy (ART) significantly reduced Human Immunodeficiency Virus (HIV) morbidity and mortality; nevertheless, stigma still characterises the living with this condition. This study explored patients' coping experience by integrating narrative medicine (NM) in a non-interventional clinical trial. From June 2018 to September 2020 the study involved 18 centres across Italy; enrolled patients were both D/C/F/TAF naïve and previously ART-treated. Narratives were collected at enrolment (V1) and last visit (V4) and then independently analysed by three NM specialist researchers through content analysis. One-hundred and fourteen patients completed both V1 and V4 narratives. Supportive relationships with clinicians and undetectable viral load facilitated coping. Conversely, lack of disclosure of HIV-positive status, HIV metaphors, and unwillingness to narrate the life before the diagnosis indicated internalised stigma. This is the first non-interventional study to include narratives as patient reported outcomes (PROs). Improving HIV awareness and reducing the sense of guilt experienced by patients helps to overcome stigma and foster coping.
© 2023. Springer Nature Limited.
Conflict of interest statement
AA had financial relationship with Astrazeneca, Gilead Sciences, Glaxo Smith Kline, Janssen, Merck, Roche, Theratechnologies, ViiV Healthcare. AV had financial relationship with Janssen-Cilag, ViiV Healthcare srl, MSD, Gilead. DR had financial relationship with Janssen, Gilead, ViiVhealthcare. VE had financial relationship with Gilead Sciences, MSD, Theratechnologies, ViiV Healthcare. MAC had financial relationship with MSD, Janssen-Cilag spa,ViiV Healthcare srl. SR had financial relationship with Gilead Sciences, Glaxo Smith Kline, Janssen, MSD, Theratechnolo-gies, ViiV Healthcare. MA had financial relationship with ViiV Healthcare srl, MSD, Gilead, GSK, Pfizer, Angelini, Janssen Tibotec. AC, LR, MGM are employee of ISTUD. MP, UA, TR, MD are employee of Janssen-Cilag Spa. DV, AC, EM and GO has none to declare.
Figures
References
-
- World Health Organization . Guideline on When to Start Antiretroviral Therapy and on Pre-exposure Prophylaxis for HIV. World Health Organizatinon; 2015. - PubMed
-
- World Health Organization . Progress Report 2016: Prevent HIV, Test and Treat All. World Health Organizatinon; 2016.
-
- Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr. Opin. Infect. Dis. 2013;26(1):17–25. - PubMed
-
- Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26:335–343. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources